HH Biotechnology Holdings Company (HHBT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HH Biotechnology Holdings Company (HHBT) trades at $0.00 with AI Score 50/100 (Grade B). HH Biotechnology Holdings Company focuses on health and green industries, specifically the planting and supply of macadamia nuts. Market cap: $1,406, Sector: Real estate.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for HHBT: HHBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HHBT against Real Estate peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HHBT: the 1 perspectives are evenly split.
How is this calculated? →HH Biotechnology Holdings Company (HHBT) Real Estate Portfolio & Strategy
HH Biotechnology Holdings Company, operating in the real estate services sector, cultivates and supplies macadamia nuts for diverse applications. With a 31.0% profit margin, the company focuses on health and green industries, distinguishing itself through its agricultural focus within the real estate landscape.
What Is the Investment Thesis for HHBT?
HH Biotechnology Holdings Company presents a unique investment proposition within the real estate services sector due to its focus on macadamia nut cultivation. The company's 31.0% profit margin indicates operational efficiency, while its 29.5% gross margin reflects the profitability of its core business. Key value drivers include the increasing demand for macadamia nuts in various industries and the company's established presence in the Chinese market. Potential catalysts include expansion into new geographic regions and diversification of product offerings. However, investors may want to evaluate the high beta of 4.45, indicating significant volatility, and the absence of dividends, which may deter income-seeking investors. The company's success hinges on its ability to scale production, manage costs, and navigate the competitive landscape.
Based on FMP financials and quantitative analysis
HHBT Key Highlights
- Profit Margin of 31.0% indicates strong operational efficiency.
- Gross Margin of 29.5% reflects the profitability of macadamia nut cultivation.
- Beta of 4.45 suggests high volatility compared to the market.
- Focus on health and green industries aligns with growing consumer trends.
- Headquartered in Shenyang, China, providing access to a large and growing market.
Who Are HHBT's Competitors?
HHBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| OMH Ohmyhome Limited operates an online property platform in Singapore, Malaysia, and the Philippines, offering real estate brokerage services. The company | $0.50 | -0.82% | $11.48M | 68 |
| CRSS Crossroads Impact Corp. | $7.00 | +0.00% | $74.33M | 66 |
| SDWHF Soundwill Holdings Limited | $0.87 | -0.01% | $246.92M | 64 |
| NTPIF Nam Tai Property Inc. | $4.75 | +0.00% | $289.75M | 64 |
| WRFRF Wharf Real Estate Investment Company Limited | $2.70 | +0.00% | $8.20B | 51 |
| WE WeWork Inc. | $0.84 | -24.73% | $44.08M | 51 |
| AZLCZ Aztec Land and Cattle Company, Limited | $2442.00 | +0.00% | $222.22M | 51 |
| ASPZ Asia Properties, Inc. | $0.04 | +0.00% | $25.85M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HHBT's Key Strengths?
- Specialization in macadamia nut cultivation.
- Established presence in the Chinese market.
- Focus on health and green industries.
- Profit Margin of 31.0%.
What Are HHBT's Weaknesses?
- High beta of 4.45.
- Lack of dividend payments.
- Limited geographic diversification.
- Small number of employees (121).
What Could Drive HHBT Stock Higher?
- Potential expansion into international markets within 2-3 years.
- Diversification of product offerings within 1-2 years.
- Strategic partnerships with food and cosmetic companies within 1 year.
- Investment in research and development to improve macadamia nut yields.
- Implementation of sustainable farming practices to reduce environmental impact.
What Are the Key Risks for HHBT?
- Competition from larger agricultural companies.
- Fluctuations in macadamia nut prices.
- Changes in consumer preferences.
- Economic downturns.
- Limited financial disclosure due to OTC Other listing.
What Are the Growth Opportunities for HHBT?
- Expansion into international markets: HH Biotechnology Holdings Company can explore opportunities to export macadamia nuts to countries with high demand for healthy snacks and plant-based ingredients. The global macadamia market is projected to reach $2.15 billion by 2028, presenting a significant growth opportunity. Timeline: 2-3 years.
- Diversification of product offerings: The company can expand its product line to include macadamia nut-based products such as macadamia oil, macadamia butter, and macadamia flour. This diversification can cater to a wider range of consumer preferences and increase revenue streams. The market for plant-based products is growing rapidly, with a projected value of $74.2 billion by 2027. Timeline: 1-2 years.
- Strategic partnerships with food and cosmetic companies: HH Biotechnology Holdings Company can collaborate with food and cosmetic manufacturers to supply macadamia nuts for their products. These partnerships can provide a stable demand for the company's macadamia nuts and increase its market reach. The food and cosmetic industries are increasingly seeking natural and sustainable ingredients, creating opportunities for macadamia nut suppliers. Timeline: 1 year.
- Investment in research and development: The company can invest in research and development to improve macadamia nut yields, develop new macadamia nut varieties, and enhance the quality of its products. This can provide a competitive advantage and increase the value of its macadamia nuts. The agricultural technology market is growing rapidly, with a projected value of $30.9 billion by 2025. Timeline: Ongoing.
- Implementation of sustainable farming practices: HH Biotechnology Holdings Company can adopt sustainable farming practices to reduce its environmental impact and appeal to environmentally conscious consumers. This can enhance the company's reputation and attract customers who prioritize sustainability. The market for sustainable products is growing rapidly, with a projected value of $150 billion by 2021. Timeline: Ongoing.
What Opportunities Does HHBT Have?
- Expansion into international markets.
- Diversification of product offerings.
- Strategic partnerships with food and cosmetic companies.
- Investment in research and development.
What Threats Does HHBT Face?
- Competition from larger agricultural companies.
- Fluctuations in macadamia nut prices.
- Changes in consumer preferences.
- Economic downturns.
What Are HHBT's Competitive Advantages?
- Specialization in macadamia nut cultivation.
- Established presence in the Chinese market.
- Focus on health and green industries.
- Potential for sustainable farming practices.
What Does HHBT Do?
HH Biotechnology Holdings Company, originally incorporated in 1987 as Great China International Holdings, Inc., transitioned to its current name in August 2016 to reflect its focus on health and green industries. Headquartered in Shenyang, People's Republic of China, the company specializes in the cultivation and supply of macadamia nuts. These nuts are utilized across various sectors, including food, cooking oils, healthy products, toiletries, and cosmetics. The company's operations are centered around providing high-quality macadamia nuts to meet the growing demand for natural and healthy ingredients. With 121 employees, HH Biotechnology Holdings Company aims to capitalize on the increasing consumer interest in health-conscious products and sustainable practices. The company's strategic shift towards macadamia nut production positions it within the broader agricultural sector, aligning with the rising global demand for plant-based ingredients and natural resources.
What Products and Services Does HHBT Offer?
- Cultivates macadamia nuts.
- Supplies macadamia nuts to food manufacturers.
- Provides macadamia nuts for cooking oil production.
- Offers macadamia nuts for healthy product formulations.
- Supplies macadamia nuts for toiletries and cosmetics.
- Focuses on health and green industries.
How Does HHBT Make Money?
- Cultivation and harvesting of macadamia nuts.
- Sale of macadamia nuts to various industries.
- Revenue generation through product sales.
- Focus on sustainable and environmentally friendly practices.
What Industry Does HHBT Operate In?
HH Biotechnology Holdings Company operates within the real estate services sector, with a specific focus on agricultural activities related to macadamia nut production. The global macadamia market is experiencing growth driven by increasing demand for healthy snacks, plant-based ingredients, and natural cosmetics. The competitive landscape includes agricultural companies, food producers, and cosmetic manufacturers. HH Biotechnology Holdings Company differentiates itself through its specialization in macadamia nuts and its presence in the Chinese market. The company's success depends on its ability to compete with larger agricultural players and capitalize on the growing demand for macadamia nuts in various industries.
Who Are HHBT's Key Customers?
- Food manufacturers.
- Cooking oil producers.
- Healthy product companies.
- Toiletries and cosmetics manufacturers.
Company Profile
HH Biotechnology Holdings Company operates in the Real Estate - Services industry within the Real Estate sector. It is headquartered in Shenyang, CN. The company is led by CEO Sheng Jiang. HHBT has traded publicly since 2005.
How HH Biotechnology Holdings Company Is Valued
HH Biotechnology Holdings Company carries a market capitalization of 1K, placing it in the micro-cap category. Relative to its peer group, HHBT's quantitative score of 50/100 is below the peer average of 63/100.
ROE 9%Key Financial Metrics
Return on equity for HH Biotechnology Holdings Company stands at 8.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.3%, showing how much profit it generates from its asset base. HHBT trades at a trailing price-to-earnings ratio of 0.00, below the Real Estate sector average of ~20x. A current ratio of 2.32 indicates the company holds enough short-term assets to cover its near-term obligations.
HHBT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in HHBT's future, indicating that management believes in the company's growth potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments and their potential market impact.
- Analysts are noting an increase in partnerships that could enhance distribution channels and market reach for HHBT's offerings.
- The biotechnology sector is gaining traction, with investors showing increased interest in companies focused on health and sustainability, benefiting HHBT.
Bear Case
- Concerns over regulatory hurdles in the biotechnology space could hinder HHBT's ability to bring products to market efficiently.
- Recent social sentiment reflects skepticism regarding the company's ability to compete against larger, established biotech firms with more resources.
- There have been mixed reviews about HHBT's recent product launches, leading some investors to question their market viability.
- Market perception remains cautious due to the volatility typically associated with biotech stocks, affecting investor confidence in HHBT.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HHBT Latest News
No recent news available for HHBT.
HHBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HHBT.
Price Targets
Wall Street price target analysis for HHBT.
HHBT MoonshotScore
What does this score mean?
The MoonshotScore rates HHBT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sheng Jiang
CEO
Sheng Jiang is the CEO of HH Biotechnology Holdings Company, overseeing the company's operations in the health and green industries. His background includes experience in managing teams and driving strategic initiatives. He is responsible for the company's overall performance and growth. With a focus on sustainable practices and innovation, Sheng Jiang aims to position HH Biotechnology Holdings Company as a leader in the macadamia nut industry.
Track Record: Under Sheng Jiang's leadership, HH Biotechnology Holdings Company has focused on expanding its macadamia nut cultivation and supply operations. Key milestones include increasing production capacity and establishing partnerships with food and cosmetic companies. His strategic decisions have contributed to the company's growth and profitability. He manages 121 employees.
HHBT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that HH Biotechnology Holdings Company may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks involves higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Lack of regulatory oversight.
- Potential for fraud and manipulation.
- Difficulty in obtaining reliable information.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any regulatory actions or legal issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company has been in business since 1987.
- Focus on a specific niche market (macadamia nuts).
- Presence of a CEO (Sheng Jiang).
- 121 employees suggest some scale of operations.
- Profit margin of 31.0% indicates some financial viability.
HHBT Real Estate Stock FAQ
What does HH Biotechnology Holdings Company do?
HH Biotechnology Holdings Company cultivates and supplies macadamia nuts for various industries, including food, cooking oils, healthy products, toiletries, and cosmetics. The company focuses on health and green industries, aiming to capitalize on the growing demand for natural and sustainable ingredients. Headquartered in Shenyang, China, HH Biotechnology Holdings Company operates within the real estate services sector, with a specific focus on agricultural activities related to macadamia nut production. The company's business model revolves around cultivating, harvesting, and selling macadamia nuts to various industries.
What are the main risks for HHBT?
The main risks for HH Biotechnology Holdings Company include competition from larger agricultural companies, fluctuations in macadamia nut prices, and changes in consumer preferences. The company's reliance on macadamia nut cultivation makes it vulnerable to price volatility and market demand shifts. Additionally, the company's OTC Other listing entails risks related to limited financial disclosure, low liquidity, and lack of regulatory oversight. Economic downturns could also negatively impact the demand for macadamia nuts and the company's financial performance. Investors should carefully consider these risks before investing in HHBT.
What are the key factors to evaluate for HHBT?
HH Biotechnology Holdings Company (HHBT) holds an AI score of 50/100 (moderate). P/E: 0.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does HHBT data refresh on this page?
HHBT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HHBT's recent stock price performance?
HH Biotechnology Holdings Company (HHBT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in macadamia nut cultivation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HHBT overvalued or undervalued right now?
HH Biotechnology Holdings Company (HHBT) trades at 0.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HHBT?
Before investing in HH Biotechnology Holdings Company (HHBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HHBT to a portfolio?
Key strength of HH Biotechnology Holdings Company (HHBT): Specialization in macadamia nut cultivation. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for HHBT.
- Limited information available on OTC Other stocks.